Anti-b7h3 and cmet antibody, and antibody-drug conjugate and use thereof
WO2026149547A1PCT designated stage Publication Date: 2026-07-16SHANDONG SIMCERE ZAIMING BIOPHARMACEUTICAL CO LTD
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- SHANDONG SIMCERE ZAIMING BIOPHARMACEUTICAL CO LTD
- Filing Date
- 2026-01-09
- Publication Date
- 2026-07-16
AI Technical Summary
Technical Problem
In the existing technology, small molecule drugs that inhibit cMET signaling are not ideal for the treatment of tumors, and cMET and B7H3 are not highly expressed in normal tissues, which limits the scope of targeted therapy.
Method used
Develop bispecific antibodies against B7H3 and cMET and their antibody-drug conjugates (ADCs) to expand the treatment population by simultaneously targeting B7H3 and cMET. Utilize bioinformatics analysis to design multispecific antibodies and combine them with cytotoxic drugs to enhance antitumor activity.
Benefits of technology
It has achieved broad-spectrum treatment of a variety of tumors, improved anti-tumor activity, expanded the potential treatment population, and enhanced the killing effect on tumors expressing B7H3 and cMET.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure PCTCN2026071700-FTAPPB-I100001 
Figure PCTCN2026071700-FTAPPB-I100002 
Figure PCTCN2026071700-FTAPPB-I100003
Abstract
Provided is a bispecific antibody capable of specifically binding to B7H3 and cMET. The bispecific antibody can simultaneously target B7H3 and cMET, and may be a new tumor treatment strategy. In addition, also provided are an antibody drug conjugate (ADC) of the bispecific antibody, a polynucleotide encoding the bispecific antibody, a vector, a host cell, and a pharmaceutical composition comprising the bispecific antibody or the ADC thereof.
Need to check novelty before this filing date? Find Prior Art